In case study reports of EML4-ALK-positive NSCLC patients who underwent sequential monitoring during therapy with ALK inhibitors, it was found that EML4-ALK-positive CTCs reflect the response to these inhibitors and predict treatment resistance [206,207]. The gene discussed is EML4; the disease is non-small cell lung carcinoma.